190 related articles for article (PubMed ID: 27805828)
1. The adverse outcome pathway for skin sensitisation: Moving closer to replacing animal testing.
Schultz TW; Dimitrova G; Dimitrov S; Mekenyan OG
Altern Lab Anim; 2016 Oct; 44(5):453-460. PubMed ID: 27805828
[TBL] [Abstract][Full Text] [Related]
2. The use of peptide reactivity assays for skin sensitisation hazard identification and risk assessment.
Gerberick GF
Altern Lab Anim; 2016 Oct; 44(5):437-442. PubMed ID: 27805826
[TBL] [Abstract][Full Text] [Related]
3. Development of an in silico profiler for respiratory sensitisation.
Enoch SJ; Roberts DW; Madden JC; Cronin MT
Altern Lab Anim; 2014 Dec; 42(6):367-75. PubMed ID: 25635645
[TBL] [Abstract][Full Text] [Related]
4. Applying the skin sensitisation adverse outcome pathway (AOP) to quantitative risk assessment.
Maxwell G; MacKay C; Cubberley R; Davies M; Gellatly N; Glavin S; Gouin T; Jacquoilleot S; Moore C; Pendlington R; Saib O; Sheffield D; Stark R; Summerfield V
Toxicol In Vitro; 2014 Feb; 28(1):8-12. PubMed ID: 24184331
[TBL] [Abstract][Full Text] [Related]
5. From pathways to people: applying the adverse outcome pathway (AOP) for skin sensitization to risk assessment.
MacKay C; Davies M; Summerfield V; Maxwell G
ALTEX; 2013; 30(4):473-86. PubMed ID: 24173169
[TBL] [Abstract][Full Text] [Related]
6. 2018 Lush Science Prize.
McCann J; McCann T
Altern Lab Anim; 2020 Nov; 48(1_suppl):18S-25S. PubMed ID: 33106014
[TBL] [Abstract][Full Text] [Related]
7. 2015 Lush Science Prize.
McCann J; McCann T
Altern Lab Anim; 2016 Oct; 44(5):461-468. PubMed ID: 27805829
[TBL] [Abstract][Full Text] [Related]
8. The adverse outcome pathway concept: A basis for developing regulatory decision-making tools.
Delrue N; Sachana M; Sakuratani Y; Gourmelon A; Leinala E; Diderich R
Altern Lab Anim; 2016 Oct; 44(5):417-429. PubMed ID: 27805824
[TBL] [Abstract][Full Text] [Related]
9. Standardisation of defined approaches for skin sensitisation testing to support regulatory use and international adoption: position of the International Cooperation on Alternative Test Methods.
Casati S; Aschberger K; Barroso J; Casey W; Delgado I; Kim TS; Kleinstreuer N; Kojima H; Lee JK; Lowit A; Park HK; Régimbald-Krnel MJ; Strickland J; Whelan M; Yang Y; Zuang V
Arch Toxicol; 2018 Feb; 92(2):611-617. PubMed ID: 29127450
[TBL] [Abstract][Full Text] [Related]
10. Replacing the refinement for skin sensitization testing: Considerations to the implementation of adverse outcome pathway (AOP)-based defined approaches (DA) in OECD guidelines.
Kolle SN; Landsiedel R; Natsch A
Regul Toxicol Pharmacol; 2020 Aug; 115():104713. PubMed ID: 32562760
[TBL] [Abstract][Full Text] [Related]
11. Adverse outcome pathway development from protein alkylation to liver fibrosis.
Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
[TBL] [Abstract][Full Text] [Related]
12. An integrated decision-tree testing strategy for skin sensitisation with respect to the requirements of the EU REACH legislation.
Grindon C; Combes R; Cronin MT; Roberts DW; Garrod JF
Altern Lab Anim; 2008 Oct; 36 Suppl 1():75-89. PubMed ID: 19025333
[TBL] [Abstract][Full Text] [Related]
13. Skin sensitisation, adverse outcome pathways and alternatives.
Basketter D
Altern Lab Anim; 2016 Oct; 44(5):431-436. PubMed ID: 27805825
[TBL] [Abstract][Full Text] [Related]
14. 2017 Lush Science Prize.
McCann J; McCann T
Altern Lab Anim; 2018 Sep; 46(4):199-207. PubMed ID: 30365334
[TBL] [Abstract][Full Text] [Related]
15. Probabilistic hazard assessment for skin sensitization potency by dose-response modeling using feature elimination instead of quantitative structure-activity relationships.
Luechtefeld T; Maertens A; McKim JM; Hartung T; Kleensang A; Sá-Rocha V
J Appl Toxicol; 2015 Nov; 35(11):1361-1371. PubMed ID: 26046447
[TBL] [Abstract][Full Text] [Related]
16. Reduction, refinement and replacement: putting the immune system to work.
Kimber I
Altern Lab Anim; 2002; 30(6):569-77. PubMed ID: 12511192
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of non-animal methods for assessing skin sensitisation hazard: A Bayesian Value-of-Information analysis.
Leontaridou M; Gabbert S; Van Ierland EC; Worth AP; Landsiedel R
Altern Lab Anim; 2016 Jul; 44(3):255-69. PubMed ID: 27494625
[TBL] [Abstract][Full Text] [Related]
18. SkinSensPred as a Promising in Silico Tool for Integrated Testing Strategy on Skin Sensitization.
Wang SS; Wang CC; Tung CW
Int J Environ Res Public Health; 2022 Oct; 19(19):. PubMed ID: 36232156
[TBL] [Abstract][Full Text] [Related]
19. The potential of AOP networks for reproductive and developmental toxicity assay development.
Knapen D; Vergauwen L; Villeneuve DL; Ankley GT
Reprod Toxicol; 2015 Aug; 56():52-5. PubMed ID: 25889759
[TBL] [Abstract][Full Text] [Related]
20. AOP and IATA applied to ocular surface toxicity.
Bonneau N; Baudouin C; Brignole-Baudouin F
Regul Toxicol Pharmacol; 2021 Oct; 125():105021. PubMed ID: 34348128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
